Vertex presents positive, updated vx-880 results from ongoing phase 1/2 study in type 1 diabetes at the european association for the study of diabetes 59th annual meeting

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today presented longer-term data on patients dosed in parts a and b of its phase 1/2 clinical trial of vx-880, an investigational stem cell-derived, fully differentiated islet cell therapy in people with type 1 diabetes (t1d) with impaired hypoglycemic awareness and severe hypoglycemic events (shes). prior to vx-880 treatment, all six patients enrolled had long-standing t1d with no endogenous insulin secretion, required.
VRTX Ratings Summary
VRTX Quant Ranking